Wet age-related macular degeneration (wet AMD)
RGNXRegenxbioCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for ABBV-RGX-314 (Subretinal Delivery) in Wet age-related macular degeneration (wet AMD). The expected timing is based on the latest available company guidance and may change.
ATMOSPHERE®/ASCENT/FET studies. In collab w/ AbbVie. 10/6/25- Completion of enrollment w/ topline results in Q4 2026.11/06/25:- Enrollment of >1,200 participants in ATMOSPHERE and ASCENT pivotal wet AMD trials completed. Topline Phase 3 results remain expected in Q4 2026, and program is positioned as potential first approved gene therapy for wet AMD. 03/05/26:- Q4 2026 wet AMD pivotal topline reaffirmed; global regulatory submissions planned in 2027 with AbbVie. 05/14/26:- Q4 2026 ATMOSPHERE/ASCENT subretinal wet AMD topline and 2027 global regulatory submissions reiterated. 06/29/26:- Present 5-year Ph1/2a subretinal wet AMD data at ASRS July 2026. Q4 2026 topline reaffirmed. 07/18/26:- ASRS showed 5-year Ph1/2a wet AMD durability; Q4 2026 ATMOSPHERE/ASCENT topline expected. 08/06/26:- ATMOSPHERE/ASCENT topline remains Q4 2026; global submissions expected 2027.
Verification
Confirm timing and program details against the company announcement or filing.